Neurava has developed a wearable device that continuously monitors biological signals related to epilepsy and Sudden Unexpected Death in Epilepsy (SUDEP), providing real-time alerts to caregivers. This technology enables timely data transmission to healthcare providers, facilitating expedited treatment plans for patients at risk of uncontrolled seizures.
Funding
$2.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Epilepsy patients, including the 35% who do not respond to anti-seizure medications, face the constant threat of uncontrolled seizures and related complications such as Sudden Unexpected Death in Epilepsy (SUDEP). Current monitoring methods often lack continuous, real-time data, hindering timely intervention and personalized treatment plans.
Solution
Neurava provides a wearable device that continuously tracks key biological signals associated with epilepsy and SUDEP risk. The device transmits real-time alerts to caregivers, enabling prompt response to seizure events and potential SUDEP indicators. Wireless data transmission to healthcare providers facilitates expedited treatment adjustments and proactive management of at-risk patients. This comprehensive monitoring approach offers peace of mind to caregivers through accurate and timely notifications, particularly during nighttime hours.
Target Audience
The primary target audience includes epilepsy patients at risk of uncontrolled seizures and SUDEP, their caregivers, and healthcare providers specializing in epilepsy management.
Features
- Continuous monitoring of biological signals related to epilepsy and SUDEP
- Real-time alerts to caregivers for timely intervention
- Wireless data transmission to healthcare providers for expedited treatment planning
- Nighttime monitoring for enhanced peace of mind